Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1971179 | 0.83 | ADRA1D (0.49) | ADRA1DADRA1AADRA1BHTTMEN1 | |
| SCHEMBL31305922 | 0.83 | CXCR4 (0.59) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL28661867 | 0.82 | SMN1; SMN2 (0.65) | HTTSMN1; SMN2MEN1KMT2AATM | |
| SCHEMBL17802022 | 0.81 | ADRA1D (0.48) | ADRA1DADRA1AADRA1BHTTKDM4E | |
| SCHEMBL1965727 | 0.81 | CHRM2 (0.60) | ADRA1DADRA1AADRA1BMEN1KMT2A | |
| SCHEMBL7034334 | 0.81 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BSMN1; SMN2MEN1 | |
| SCHEMBL1967608 | 0.81 | NPC1 (0.46) | ADRA1DADRA1AADRA1BSMN1; SMN2MEN1 | |
| SCHEMBL1968986 | 0.81 | L3MBTL1 (0.50) | ADRA1DADRA1AADRA1BSMN1; SMN2MEN1 | |
| SCHEMBL1965700 | 0.80 | POLB (0.59) | SMN1; SMN2MEN1KMT2AATMKDM4E | |
| SCHEMBL1971363 | 0.80 | KDM4E (0.48) | ADRA1DADRA1AADRA1BKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | ADRA1D 121/4885ADRA1A 77/4885ADRA1B 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.